• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early Remission With Induction Therapy Predicts Long-Term Remission in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.

作者信息

Mohan Babu P, Fatima Noor, Khan Shahab R, Kassab Lena, Chandan Saurabh, Asokkumar Ravishankar, Valentine John F, Navaneethan Udayakumar, Kochhar Gursimran S, Ma Christopher, Jairath Vipul, Singh Siddharth

机构信息

Gastroenterology & Hepatology, University of Utah Health, Salt Lake, City, Utah, USA.

Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

出版信息

Am J Gastroenterol. 2023 Nov 1;118(11):2084-2087. doi: 10.14309/ajg.0000000000002328. Epub 2023 May 19.

DOI:10.14309/ajg.0000000000002328
PMID:37207296
Abstract
摘要

相似文献

1
Early Remission With Induction Therapy Predicts Long-Term Remission in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.诱导治疗早期缓解可预测炎症性肠病的长期缓解：一项系统评价和荟萃分析
Am J Gastroenterol. 2023 Nov 1;118(11):2084-2087. doi: 10.14309/ajg.0000000000002328. Epub 2023 May 19.
2
Thalidomide for inflammatory bowel disease: Systematic review.沙利度胺用于炎症性肠病：系统评价
Medicine (Baltimore). 2016 Jul;95(30):e4239. doi: 10.1097/MD.0000000000004239.
3
Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review.炎症性肠病的诱导和维持治疗：全面综述。
Autoimmun Rev. 2019 May;18(5):439-454. doi: 10.1016/j.autrev.2019.03.002. Epub 2019 Mar 4.
4
Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.维多珠单抗诱导炎症性肠病缓解的疗效和安全性——以色列真实世界经验
Inflamm Bowel Dis. 2017 Mar;23(3):404-408. doi: 10.1097/MIB.0000000000001039.
5
Clinical remission in paired phase two and three studies in inflammatory bowel disease: a systematic review with meta-analysis.炎症性肠病二、三期配对研究中的临床缓解：一项荟萃分析的系统评价
Eur J Gastroenterol Hepatol. 2023 Mar 1;35(3):231-240. doi: 10.1097/MEG.0000000000002490. Epub 2022 Dec 8.
6
A Systematic Review and Meta-Analysis of 6-Thioguanine Nucleotide Levels and Clinical Remission in Inflammatory Bowel Disease.6-硫代鸟嘌呤核苷酸水平与炎症性肠病临床缓解的系统评价和荟萃分析。
J Crohns Colitis. 2017 Oct 27;11(11):1381-1392. doi: 10.1093/ecco-jcc/jjx089.
7
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.英夫利昔单抗诱导治疗期间治疗药物监测与标准治疗对慢性免疫介导性炎症疾病患者疾病缓解的影响：一项随机临床试验
JAMA. 2021 May 4;325(17):1744-1754. doi: 10.1001/jama.2021.4172.
8
Inducing remission in inflammatory bowel disease.
Drug Ther Bull. 2003 Apr;41(4):30-2. doi: 10.1136/dtb.2003.41430.
9
The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease.儿童炎症性肠病诱导治疗期间粪便钙卫蛋白值与抗肿瘤坏死因子-α治疗的长期结局
Scand J Gastroenterol. 2014 Apr;49(4):434-41. doi: 10.3109/00365521.2014.886719. Epub 2014 Mar 6.
10
Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy.诱导治疗期间英夫利昔单抗浓度可预测接受联合治疗的小儿炎症性肠病患者的内镜缓解情况。
J Pediatr. 2022 Jan;240:150-157.e4. doi: 10.1016/j.jpeds.2021.08.079. Epub 2021 Sep 3.

引用本文的文献

1
Delays in Initiating Biologic Therapy in Patients with Inflammatory Bowel Disease-Perception and Reality.炎症性肠病患者生物治疗起始延迟——认知与现实
Dig Dis Sci. 2025 Mar;70(3):1246-1247. doi: 10.1007/s10620-025-08855-w. Epub 2025 Jan 22.
2
Nutritional Management for Crohn's Disease.克罗恩病的营养管理。
Nutrients. 2024 Aug 7;16(16):2597. doi: 10.3390/nu16162597.